ImmunityBio Inc. (IBRX) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ImmunityBio Inc. (IBRX) slipped -0.79% to $8.74 as options desks priced 58% call premium vs. 42% put protection around the $9 max-pain magnet. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.
Virginia Retirement Systems raised its stakes in all three stocks, with combined holdings worth nearly $3 million at September-end.
Insmed (INSM) delivered earnings and revenue surprises of -35.29% and +4.62%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Prime Medicine, Inc. (PRME) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Jim Cramer called ImmunityBio a strong speculative buy, favored Monster over Celsius, avoided USA Rare Earth and liked Glacier Bancorp.
ImmunityBio expects November results from a 366-patient Anktiva trial and plans a fourth-quarter FDA filing.
Here is how HeartSciences Inc. (HSCS) and ImmunityBio (IBRX) have performed compared to their sector so far this year.
ImmunityBio is nearing final results from a trial testing whether adding ANKTIVA to BCG improves complete response rates and response durability in patients with BCG-naïve bladder cancer.
CULVER CITY, Calif., October 21, 2026--ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced completion of the database lock for Cohort A of QUILT-2.005 (NCT02138734), its randomized, controlled, re
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Database lock completed for Cohort A of QUILT-2.005 (NCT02138734), a randomized, controlled registrational trial comparing ANKTIVA® plus BCG with BCG alone in 366 patients with BCG-naïve non-muscle invasive bladder
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +180.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IBRX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IBRX. Explore sector supply chains on /butterfly.
Why IBRX Stock slipped -0.79% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-27% return on capital) under elevated 10-year interest-rate pressure.